Uterine Cancer Survivorship Follow-Up Questions

"Uterine cancer" covers two very different diseases, and follow-up differs between them.

Most uterine cancers are endometrial carcinomas. They start in the lining. A smaller group are uterine sarcomas. They start in the muscle or supporting tissue. Sarcoma subtypes include leiomyosarcoma, endometrial stromal sarcoma, and carcinosarcoma. Rarer ones include PEComa, a perivascular epithelial-cell tumor.

Ask which one is on your pathology report, and ask for the subtype by name. Everything below depends on that answer.

Risk of return drives the intensity of follow-up, and for sarcomas the published rates are specific.

For carcinosarcoma, NCI reports two recurrence rates. It was 44% for homologous tumors and 63% for heterologous tumors. Homologous means the sarcoma part looks like tissue normally found in the uterus. Heterologous means it does not.

For leiomyosarcoma, the markers differ. Some investigators call tumor size the most important factor. Tumors larger than 5.0 cm carry a poorer outlook. But in one Gynecologic Oncology Group study, only one factor tracked with time free of progression. That was the mitotic index, a count of dividing cells.

NCI gives one more figure, in the same passage about leiomyosarcoma. For stage I disease, confined to the body of the uterus, the 5-year survival rate is about 50%. For the remaining stages it is 0% to 20%.

These figures are not predictions about you. They explain why a sarcoma follow-up schedule is usually tighter than one for a low-grade endometrial cancer.

This is one of the few places in survivorship care with a concrete, named action.

NCI reports more uterine sarcoma in women taking tamoxifen for breast cancer. The same rise appeared when tamoxifen was given to prevent breast cancer in women at higher risk. The likely reason is tamoxifen's estrogen-like effect on the uterus.

The advice that follows is specific. People taking tamoxifen should have follow-up pelvic exams. And any abnormal uterine bleeding calls for an endometrial biopsy.

If you are on tamoxifen after breast cancer, ask which clinician owns that pelvic exam. It commonly falls between the breast team and the gynecologist and gets missed.

NCI names one documented cause. Prior pelvic radiation explains 10% to 25% of uterine sarcomas. It was often given 5 to 25 years earlier, for heavy bleeding that was not cancer.

Ask what second-cancer surveillance applies to you if you had pelvic radiation. Ask over what timeframe. The intervals here are long. The responsibility often outlives the team that treated you.

Ask your team to write down what warrants a call rather than waiting for the next appointment. Not everything on the list moves at the same speed.

Call 911 or go to an emergency department for:

• Vaginal bleeding heavy enough to soak a pad every hour or two, or bleeding that leaves you faint, grey, or clammy.
• Sudden breathlessness, chest pain, or coughing up blood. A clot on the lung can present this way, and the lungs are a common site of sarcoma spread.
• Swelling, pain, or redness in one calf or thigh, which can mean a clot in a leg vein.
• New weakness in the legs, numbness in the saddle area, or loss of bladder or bowel control, which can mean pressure on the spinal cord.
• If you are still having chemotherapy, a temperature of 100.4°F (38°C) or higher. The CDC treats fever during chemotherapy as a medical emergency, because your infection defences may be too low to hold an infection back. Say you are on chemotherapy when you arrive.

Call the same day for:

• Any vaginal bleeding or spotting after menopause or after your treatment ended.
• Discharge that is new, persistent, or foul-smelling.
• Severe pelvic or abdominal pain, or a belly that is swollen and tender.

Call within a day or two for:

• Pelvic or abdominal pain that lasts more than a week.
• New abdominal swelling or a sense of fullness.
• A cough or breathlessness that has crept up gradually over weeks.

Ask for a phone number that reaches someone within one business day, and ask what happens outside office hours.

For uterine sarcoma, NCI notes that surgery alone can cure the disease when it stays inside the uterus. The value of pelvic radiation is not established.

Chemotherapy after complete removal of stage I or II disease was not effective in a randomized trial. Nonrandomized studies have reported better survival with it, with or without radiation. That gap between trial types is worth knowing, because it explains why practice varies.

If you had chemotherapy, ask which drugs and how many cycles. Then ask what each one calls for long term. Two drugs used in uterine sarcoma carry boxed FDA warnings that shape follow-up.

Doxorubicin can damage heart muscle, including acute left ventricular failure. The FDA label for liposomal doxorubicin reports an 11% risk of cardiomyopathy at a cumulative anthracycline dose between 450 and 550 mg/m2, and directs that left ventricular function be assessed before, during, and after treatment.

Ifosfamide carries warnings for low blood counts, brain effects, kidney damage, and bladder toxicity. Its label notes that severe bleeding from the bladder can be reduced by giving mesna as a preventive drug.

• How often will I be seen, for how many years, and by which specialty?
• Is a pelvic exam part of every visit?
• Are scans scheduled, or ordered only when something changes? If scheduled, which type and how often?
• Who takes over follow-up when the oncology visits end?

Treatment for uterine cancer leaves specific issues that deserve their own plan.

Surgical menopause. If your ovaries were removed before natural menopause, the change is abrupt. Ask about hot flashes, sleep, mood, and bone health, and ask whether hormone therapy is an option for your specific cancer type. The answer differs by diagnosis, so a general answer is not enough.

Bone density. Early menopause raises fracture risk. Ask when a bone density scan is appropriate and whether calcium and vitamin D are advised.

Lymphedema. If pelvic lymph nodes were removed, leg swelling can appear months or years later. Ask for referral to a lymphedema therapist at the first sign rather than after it becomes established.

Sexual health. Dryness, narrowing after radiation, and pain are common. All are treatable. Ask by name about dilators, moisturizers, topical treatment, and pelvic floor physical therapy.

Bowel and bladder changes. Radiation to the pelvis can cause lasting urgency or frequency. These respond to treatment, so they are worth reporting rather than adapting to.

Request a treatment summary. It should list your exact diagnosis and subtype, and the stage. It should name the operation performed and say whether nodes were removed. It should give radiation fields and dose. It should list chemotherapy drugs and cycles. And it should set out the follow-up plan with dates.

Uterine sarcomas in particular are rare, and a future clinician may never have managed one. A single accurate page saves a great deal later.

For the disease overview, see uterine cancer. For what to ask if it returns, see uterine cancer recurrence questions. For general life after treatment, see survivorship.

• National Cancer Institute, Uterine Sarcoma Treatment PDQ, for clinicians, updated December 17, 2024; accessed August 11, 2026
• DailyMed, Doxorubicin hydrochloride liposome injection FDA label, accessed August 11, 2026
• DailyMed, Ifosfamide FDA label, accessed August 11, 2026
• CDC, Fever and Cancer Treatment, accessed August 13, 2026